What is claimed is:

1. A compound of formula I



(I),

wherein

Q is S and X is C, or

Q is CH and X is N;

R_1 is unsubstituted or substituted phenyl; and

R_2 is unsubstituted or substituted aryl or heteroaryl;

or a salt thereof.

2. A compound of formula I according to claim 1 wherein

Q is S and X is C, or

Q is CH and X is N;

R_1 is phenyl that is optionally substituted by hydroxy, lower alkoxy, pyrrolidinyl-lower alkoxy, piperidinyl-lower alkoxy, morpholinyl-lower alkoxy, N,N-di-lower alkylamino-lower alkyl, N,N-di-lower alkylamino-lower alkoxy or lower alkyl-piperazinyl; and

R_2 is thiophenyl or phenyl that is optionally substituted by halo, hydroxy, lower alkoxy or N,N-di-lower alkylamino-lower alkoxy;

or a salt thereof.

3. A compound of formula I according to claim 1, wherein

Q is S and X is C, or

Q is CH and X is N;

R_1 is phenyl that is optionally substituted by one or more radicals selected from the group consisting of hydroxy, lower alkyl, halogen-lower alkyl, lower alkoxy, pyrrolidinyl-lower alkoxy wherein the pyrrolidinyl moiety is optionally substituted by lower alkyl, piperidinyl-lower alkoxy, morpholinyl-lower alkoxy, N,N-di-lower alkylamino-lower alkyl, N,N-di-lower alkylamino-lower alkoxy and lower alkyl-piperazinyl; and

R_2 is thiophenyl or phenyl that is optionally substituted by halo, hydroxy, lower alkoxy or N,N-di-lower alkylamino-lower alkoxy;
or a salt thereof.

4. A compound of formula I according to claim 1, selected from the group consisting of
(5-phenyl-thiazol-2-yl)- [4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine;
(3-dimethylaminomethyl-phenyl)-(5-phenyl-thiazol-2-yl)-amine;
[5-(4-methoxy-phenyl)-thiazol-2-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine;
(4-methoxy-phenyl)-[5-(4-methoxy-phenyl)-thiazol-2-yl]-amine;
[5-(4-methoxy-phenyl)-thiazol-2-yl]-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;
[4-(2-dimethylamino-ethoxy)-phenyl]-[5-(4-methoxy-phenyl)thiazol-2-yl]-amine;
4-{2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-thiazol-5-yl}-phenol;
{5-[4-(3-dimethylamino-propoxy)-phenyl]-thiazol-2-yl}-phenyl-amine;
4-[5-(3-methoxy-phenyl)-thiazol-2-ylamino]-phenol;
4-[5-(3-methoxy-phenyl)-thiazol-2-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]amine;
(4-methoxy-phenyl)-(5-thiophen-3-yl-thiazol-2-yl)-amine;
4-(5-thiophen-3-yl-thiazol-2-yl-amino)-phenol;
[4-(2-dimethylamino-ethoxy)-phenyl]-(5-thiophen-3-yl-thiazol-2-yl)-amine;
[4-(3-dimethylamino-propoxy)-phenyl]-(5-thiophen-3-yl-thiazol-2-yl)-amine;
[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-(5-thiophen-3-yl-thiazol-2-yl)-amine;
[4-(2-piperidin-1-yl-ethoxy)-phenyl]-(5-thiophen-3-yl-thiazol-2-yl)-amine;
[4-(2-diisopropylamino-ethoxy)-phenyl]-(5-thiophen-3-yl-thiazol-2-yl)-amine;
[4-(2-morpholin-4-yl-ethoxy)-phenyl]-(5-thiophen-3-yl-thiazol-2-yl)-amine;
(5-phenyl-1H-pyrazol-3-yl)-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]amine;
[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-(5-thiophen-3-yl-1H-pyrazol-3-yl)-amine;
[4-(2-dimethylamino-ethoxy)-phenyl]-(5-thiophen-3-yl-1H-pyrazol-3-yl)-amine;
[4-(3-dimethylamino-propoxy)-phenyl]-(5-thiophen-3-yl-1H-pyrazol-3-yl)-amine;
[4-(2-diethylamino-ethoxy)-phenyl]-(5-thiophen-3-yl-1H-pyrazol-3-yl)-amine;
[5-(2-chloro-phenyl)-1H-pyrazol-3-yl]-phenyl-amine;
[5-(2-chloro-phenyl)-1H-pyrazol-3-yl]-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine;
and pharmaceutically acceptable salts of these compounds.

5. A compound of formula I according to claim 1, selected from the group consisting of
(3-dimethylaminomethyl-phenyl)-(5-thiophen-3-yl-thiazol-2-yl)-amine;

[4-(4-methyl-piperazin-1-yl)-phenyl]-(5-thiophen-3-yl-thiazol-2-yl)-amine;
[4-(2-diethylamino-ethoxy)-phenyl]-(5-thiophen-3-yl-thiazol-2-yl)-amine;
{4-[2-(1-methyl-pyrrolidin-2-yl)-ethoxy]-phenyl}-(5-thiophen-3-yl-thiazol-2-yl)-amine;
4-[[3-(4-Methyl-piperazin-1-yl)-propyl]-(5-thiophen-3-yl-thiazol-2-yl)-amino]-phenol;
[5-(3-bromo-phenyl)-thiazol-2-yl]-[4-(2-diethylamino-ethoxy)-phenyl]-amine;
[5-(2-chloro-phenyl)-thiazol-2-yl]-[4-(2-diethylamino-ethoxy)-phenyl]-amine;
[4-(4-methyl-piperazin-1-yl)-phenyl]-[5-(3-thiophen-3-yl-phenyl)-thiazol-2-yl]-amine;
[4-(2-diethylamino-ethoxy)-phenyl]-[5-(3-thiophen-3-yl-phenyl)-thiazol-2-yl]-amine;
[4-(2-dimethylamino-ethoxy)-2-methyl-phenyl]-(5-thiophen-3-yl-thiazol-2-yl)-amine;
4-(3-dimethylamino-propoxy)-2-trifluoromethyl-phenyl]-(5-thiophen-3-yl-thiazol-2-yl)-amine;
[4-(2-dimethylamino-ethoxy)-2-trifluoromethyl-phenyl]-(5-thiophen-3-yl-thiazol-2-yl)-amine;
[4-(2-diethylamino-ethoxy)-2-trifluoromethyl-phenyl]-(5-thiophen-3-yl-thiazol-2-yl)-amine;
[4-(2-diisopropylamino-ethoxy)-2-trifluoromethyl-phenyl]-(5-thiophen-3-yl-thiazol-2-yl)-amine;
[4-(2-pyrrolidin-1-yl-ethoxy)-2-trifluoromethyl-phenyl]-(5-thiophen-3-yl-thiazol-2-yl)-amine;
[4-(2-diethylamino-ethoxy)-phenyl]-(5-thiophen-2-yl-1H-pyrazol-3-yl)-amine;
and pharmaceutically acceptable salts of these compounds.

6. A compound of formula I, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 5 for use in a method for the treatment of the human or animal body.

7. A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, together with at least one pharmaceutically acceptable carrier.

8. Use of a compound of formula I according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of a proliferative disease.

9. Use of a compound of formula I according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of a disease which responds to an inhibition of the Flt-3 kinase.

10. A process for the preparation of a compound of formula I according to claim 1 or of a salt of such a compound, characterized in that

(a) in order to prepare a compound of formula I wherein Q is S and X is C, a compound of formula II



(II),

wherein R_1 is as defined for a compound of formula I according to claim 1, is reacted with a compound of the formula R_2-CH(Hal)-C(=O)-H, wherein Hal is halo and R_2 is as defined for a compound of formula I according to claim 1;

(b) in order to prepare a compound of formula I wherein R_2 is phenyl substituted by unsubstituted or substituted lower alkoxy wherein phenyl may be optionally further substituted, a compound of formula III



(III),

wherein R_1, Q and X have the meanings as defined for a compound of formula I according to claim 1 and the phenyl ring of the compound of formula III may in addition to the hydroxy group be optionally further substituted, is reacted with halo-lower alkyl, wherein the lower alkyl moiety is optionally substituted;

(c) in order to prepare a compound of formula I wherein R_1 is phenyl substituted by unsubstituted or substituted lower alkoxy wherein phenyl may be optionally further substituted, a compound of formula IV



(IV),

wherein R_2, Q and X have the meanings as defined for a compound of formula I according to claim 1 and the phenyl ring of the compound of formula III may in addition to the hydroxy group be optionally further substituted, is reacted with halo-lower alkyl, wherein the lower alkyl moiety is optionally substituted;

(d) in order to prepare a compound of formula I wherein Q is S and X is C, a compound of formula V



(V),

wherein Hal is halo and R_1 is as defined for a compound of formula I according to claim 1, is reacted with R_2–$B(OH)_2$, wherein R_2 is as defined for a compound of formula I according to claim 1; or

(e) in order to prepare a compound of formula I wherein Q is CH and X is N, a compound of formula VI



(VI),

wherein R_1 and R_2 have the meanings as defined for a compound of formula I according to claim 1, is reacted with hydrazine;

wherein functional groups which are present in the starting compounds of processes (a) to (e) and are not intended to take part in the reaction, are present in protected form if necessary, and protecting groups that are present are cleaved, wherein said starting compounds may also exist in the form of salts provided that a salt-forming group is present and a reaction in salt form is possible;

and, if so desired, a compound of formula I thus obtained is converted into another compound of formula I, a free compound of formula I is converted into a salt, an obtained salt of a compound of formula I is converted into the free compound or another salt, and/or a mixture of isomeric compounds of formula I is separated into the individual isomers.